



Please type a number inside this box →



PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 2

Complete if Known

Application Number	09/771,701
Filing Date	January 30, 2001
First Named Inventor	COATES et al.
Group Art Unit	1614
Examiner Name	Not Yet Assigned
Attorney Docket Number	IAFG 14 C2

RECEIVED
AUG 17 2001
ENTER 1600 2900

RECEIVED

U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
FL		5,869,461		Cheng et al.	02-09-99	
		5,859,021		Cameron et al.	01-12-99	
		5,756,478		Cheng et al.	05-26-98	
		5,627,186		Cameron et al.	05-06-97	
		5,539,116		Liotta et al.	07-23-96	
		5,204,466		Liotta et al.	4-20-93	
		5,047,407		Belleau et al.	9-10-91	
		5,039,667		Tyrrell et al.	08-13-91	
		4,336,881		Nagata et al.	06-22-82	
FL		6,180,639		Coates et al.	1-30-01	

FOREIGN PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Te
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
FL		EP	0 212 409 B1			03-04-87		
		EP	0 302 760			02-08-89		
		EP	0 337 713 A2			10-18-89		
		EP	0 349 242 A2			01-03-90		
		EP	0 363 582 A1			04-18-90		
		EP	0 382 526 A2			08-16-90		
		EP	0 421 777			04-10-91		
		GB	2 063 257 A			06-03-81		
		GB	2 230 266 A			10-17-90		
		WO	89/04662			06-01-89		
		WO	90/12023			10-18-90		
		WO	91/00282			01-10-91		
		WO	91/01326			02-07-91		
FL		WO	91/11186			08-08-91		

Examiner
Signature

Krass

Date
Considered

06/02

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please place (+) inside this box → ☐

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 2

Complete If Known

Application Number	09/771,701
Filing Date	January 30, 2001
First Named Inventor	COATES et al.
Group Art Unit	1614
Examiner Name	Not Yet Assigned
Attorney Docket Number	IAFG 14 C2

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
FK		Beach et al., "Synthesis of Enantiomerically Pure (2'R,5'S,-)-1-[Hydroxymethyl]oxathiolan-5-yl]cytosine as a Potent Antiviral Agent against Hepatitis B Virus (HBV) and Human Immunodeficiency Virus (HIV)," J. Org. Chem. 1992, 57, 2217-2219	
		Chang et al., "Deoxycytidine Deaminase-resistant Stereoisomer Is the Active Form of (±)-2',3'-Dideoxy-3'-thiacytidine in the Inhibition of Hepatitis B Virus Replication," Journal of Biological Chemistry, July 15, 1992, Vol. 267, No. 20	
		Schinazi et al., "Activities of the Four Optical Isomers of 2',3'-Dideoxy-3'-Thiacytidine (BCH-189) against Human Immunodeficiency Virus Type 1 in Human Lymphocytes," Antimicrobial Agents & Chemotherapy, March 1992, Volume 36, No. 3, pp. 672-676 (1992)	
		Baba et al., "Both 2',3'-Dideoxythymidine and its 2',3'-Unsaturated Derivative (2',3'-Dideoxythymidine) are Potent and Selective Inhibitors of Human Immunodeficiency Virus Replication In Vitro", Biochemical and Biophysical Research Communications, 142(1) pp. 128-134 (1987) ("Baba")	
		Balzarini et al., "Potent and Selective Anti-HTLV-III/LAV Activity of 2',3'-Dideoxycytidine, the 2',3'-Unsaturated Derivative of 2',3'-Dideoxycytidine", Biochemical and Biophysical Research Communications, 140(2), pp. 735-742 (1986)	
		Belleau et al., "Design and Activity Of a Novel Class of Nucleoside Analogous Effective Against HIV-1", Fifth International Conference on AIDS, Montreal, Canada, Abstract T.C.O. 1 (1989)	
		Carlisle et al., "Cellular Pharmacology Of the Anti-HIV Agent BCH-189 (2' Deoxy-3'-Thiacytidine) in Human Peripheral Blood Mononuclear Cells (PBMC)", American Association for Cancer Research Proceedings, 31, abstract 2435, (1990)	
		Gosselin et al., "Systematic Synthesis and Biological Evaluation of α- and β-D-Lyxofuranosyl Nucleotides Of The Five Naturally Occurring Nucleic Acid Bases", J. Med. Chem., 30, pp. 982-991 (1987)	
		Herdewijn et al., "3'-Substituted 2',3'-Dideoxynucleoside Analogues as Potential anti-HIV (HTLV-III/LAV) Agents", J. Med. Chem., 30, pp. 1270-1278 (1987)	
		Lin et al., "Synthesis and Antiviral Activity of Various 3'-Azido, 3'-Amino, 2',3'-Unsaturated, and 2',3'-Dideoxy Analogues of Pyrimidine Deoxyribonucleosides against Retroviruses", J. Med. Chem., 30, pp. 440-444 (1987)	
		Mitsuya et al., "3'-Azido-3'-Deoxythymidine (BW A509U): An Antiviral Agent that Inhibits the Infectivity and Cytopathic Effect of Human T-Lymphotropic Virus Type III/Lymphadenopathy-Associated Virus In Vitro", Proc. Natl. Acad. Sci. USA, 82, pp. 7096-7100 (1986)	
		Mitsuya et al., "Inhibitors of the In Vitro Infectivity and Cytopathic Effect of Human T-Lymphotropic Virus Type III/Lymphadenopathy-Associated Virus (HTLV-III/LAV) by 2',3'-Dideoxynucleosides", Proc. Natl. Acad. Sci. USA, 83, pp. 1911-1915 (1986)	
		Wainberg et al., "Anti-HIV Activity, Toxicity And Pharmacokinetics Of Totally Novel Nucleoside Analogs," Fifth International Conference on AIDS, Montreal, Canada, Abstract M.C.P. 63, p. 552, (1986)	
		Wainberg et al., "Characterization of AZT-Resistant Isolates of HIV-1: Susceptibility to Deoxythiacytidine and Other Nucleosides", Sixth International Conference on AIDS, San Francisco, California, Volume 3, Abstract S.B. 87, p. 117 (1990)	
		Cleq, AIDS Research and Human Retroviruses, Vol. 8, No. 2, 1992, pp. 119-134.	
FK		J. Jacques et al., "Enantiomers, Racemates and Resolutions," John Wiley & Sons (1981).	

Examiner Signature

Krass

Date Considered

06/02

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.